Abstract: Objective The aim of this study was to investigate the long-term curative effects of transarterial embolization with pingyangmycin-lipiodol suspension (PLS) in the treatment of patients with hepatic hemangioma (HH). Methods A total of 56 patients with HH were enrolled in our hospital between February 2012 and December 2016, and were divided into two groups. 28 patients with HH were treated by transarterial embolization with PLS, and another 28 were with bleomycin-lipiodol suspension (BLS), and all patients were followed-up for 36 months. The clinical curative effects, incidences of postoperative complications and reduction of maximum tumor diameter were recorded in the two groups. Results At the end of six month after treatment, the total effective rate in PLS-treated patients was significantly higher than that in BLS-treated patients (89.3% vs. 64.3%, P<0.05), and at the end of thirty-six month after treatment, there was no significant difference as respect to the effective rates in the two groups (96.4% vs. 92.9%, P＞0.05); there was no significant difference in total complications after operation in the two groups (25.0% vs. 14.3%, P＞0.05); at the end of six month, twelve month and twenty-four month after treatment, the tumor diameters in PLS-treated patients were (7.3±0.5)cm,(5.6±0.7)cm and (3.4±1.4)cm, all significantly smaller than [(8.1±0.7)cm,(7.3±1.2)cm and (4.5±0.7), respectively, P<0.05] in BLS-treated patients, while at the end of thirty-six month, the tumor diameters in the two groups were not significantly different [(1.9±0.3)cm vs. (2.4±0.5)cm, P＞0.05]. Conclusion PLS and BLS by transarterial embolization both have comparable long-term effects in treatment of patients with HH, and the PLS seems work early, which needs further clinical observation.

Key words: Hepatic hemangioma, Pingyangmycin-lipiodol suspension, Bleomycin-lipiodol suspension, Transarterial embolization, Therapy